These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

227 related articles for article (PubMed ID: 29309658)

  • 1. Genetic background influences cardiac phenotype in murine chronic kidney disease.
    Neuburg S; Dussold C; Gerber C; Wang X; Francis C; Qi L; David V; Wolf M; Martin A
    Nephrol Dial Transplant; 2018 Jul; 33(7):1129-1137. PubMed ID: 29309658
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Induction of cardiac FGF23/FGFR4 expression is associated with left ventricular hypertrophy in patients with chronic kidney disease.
    Leifheit-Nestler M; Große Siemer R; Flasbart K; Richter B; Kirchhoff F; Ziegler WH; Klintschar M; Becker JU; Erbersdobler A; Aufricht C; Seeman T; Fischer DC; Faul C; Haffner D
    Nephrol Dial Transplant; 2016 Jul; 31(7):1088-99. PubMed ID: 26681731
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Activation of Cardiac Fibroblast Growth Factor Receptor 4 Causes Left Ventricular Hypertrophy.
    Grabner A; Amaral AP; Schramm K; Singh S; Sloan A; Yanucil C; Li J; Shehadeh LA; Hare JM; David V; Martin A; Fornoni A; Di Marco GS; Kentrup D; Reuter S; Mayer AB; Pavenstädt H; Stypmann J; Kuhn C; Hille S; Frey N; Leifheit-Nestler M; Richter B; Haffner D; Abraham R; Bange J; Sperl B; Ullrich A; Brand M; Wolf M; Faul C
    Cell Metab; 2015 Dec; 22(6):1020-32. PubMed ID: 26437603
    [TBL] [Abstract][Full Text] [Related]  

  • 4. S100/Calgranulin-mediated inflammation accelerates left ventricular hypertrophy and aortic valve sclerosis in chronic kidney disease in a receptor for advanced glycation end products-dependent manner.
    Yan L; Mathew L; Chellan B; Gardner B; Earley J; Puri TS; Hofmann Bowman MA
    Arterioscler Thromb Vasc Biol; 2014 Jul; 34(7):1399-411. PubMed ID: 24855059
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Vitamin D treatment attenuates cardiac FGF23/FGFR4 signaling and hypertrophy in uremic rats.
    Leifheit-Nestler M; Grabner A; Hermann L; Richter B; Schmitz K; Fischer DC; Yanucil C; Faul C; Haffner D
    Nephrol Dial Transplant; 2017 Sep; 32(9):1493-1503. PubMed ID: 28339837
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hypericin Alleviates Chronic Kidney Disease-induced Left Ventricular Hypertrophy by Regulation of FGF23-FGFR4 Signaling Pathway.
    Liu M; Cheng L; Ye Q; Liu H; Shu C; Gao H; Liu X; Zhang X; Chen G
    J Cardiovasc Pharmacol; 2024 Jun; 83(6):588-601. PubMed ID: 38547517
    [TBL] [Abstract][Full Text] [Related]  

  • 7. FGF23/FGFR4-mediated left ventricular hypertrophy is reversible.
    Grabner A; Schramm K; Silswal N; Hendrix M; Yanucil C; Czaya B; Singh S; Wolf M; Hermann S; Stypmann J; Di Marco GS; Brand M; Wacker MJ; Faul C
    Sci Rep; 2017 May; 7(1):1993. PubMed ID: 28512310
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Left ventricular hypertrophy in experimental chronic kidney disease is associated with reduced expression of cardiac Kruppel-like factor 15.
    Patel SK; Velkoska E; Gayed D; Ramchand J; Lesmana J; Burrell LM
    BMC Nephrol; 2018 Jul; 19(1):159. PubMed ID: 29970016
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Increased Circulating FGF23 Does Not Lead to Cardiac Hypertrophy in the Male Hyp Mouse Model of XLH.
    Liu ES; Thoonen R; Petit E; Yu B; Buys ES; Scherrer-Crosbie M; Demay MB
    Endocrinology; 2018 May; 159(5):2165-2172. PubMed ID: 29635291
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ferric citrate reduces fibroblast growth factor 23 levels and improves renal and cardiac function in a mouse model of chronic kidney disease.
    Francis C; Courbon G; Gerber C; Neuburg S; Wang X; Dussold C; Capella M; Qi L; Isakova T; Mehta R; Martin A; Wolf M; David V
    Kidney Int; 2019 Dec; 96(6):1346-1358. PubMed ID: 31668632
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Exploring the implications of blocking renin-angiotensin-aldosterone system and fibroblast growth factor 23 in early left ventricular hypertrophy without chronic kidney disease.
    Watanabe K; Fujii H; Okamoto K; Kono K; Goto S; Nishi S
    Front Endocrinol (Lausanne); 2023; 14():1276664. PubMed ID: 38174329
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Longitudinal evaluation of FGF23 changes and mineral metabolism abnormalities in a mouse model of chronic kidney disease.
    Stubbs JR; He N; Idiculla A; Gillihan R; Liu S; David V; Hong Y; Quarles LD
    J Bone Miner Res; 2012 Jan; 27(1):38-46. PubMed ID: 22031097
    [TBL] [Abstract][Full Text] [Related]  

  • 13. FGF23 induces left ventricular hypertrophy.
    Faul C; Amaral AP; Oskouei B; Hu MC; Sloan A; Isakova T; Gutiérrez OM; Aguillon-Prada R; Lincoln J; Hare JM; Mundel P; Morales A; Scialla J; Fischer M; Soliman EZ; Chen J; Go AS; Rosas SE; Nessel L; Townsend RR; Feldman HI; St John Sutton M; Ojo A; Gadegbeku C; Di Marco GS; Reuter S; Kentrup D; Tiemann K; Brand M; Hill JA; Moe OW; Kuro-O M; Kusek JW; Keane MG; Wolf M
    J Clin Invest; 2011 Nov; 121(11):4393-408. PubMed ID: 21985788
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment of established left ventricular hypertrophy with fibroblast growth factor receptor blockade in an animal model of CKD.
    Di Marco GS; Reuter S; Kentrup D; Grabner A; Amaral AP; Fobker M; Stypmann J; Pavenstädt H; Wolf M; Faul C; Brand M
    Nephrol Dial Transplant; 2014 Nov; 29(11):2028-35. PubMed ID: 24875663
    [TBL] [Abstract][Full Text] [Related]  

  • 15. FGF23-Mediated Activation of Local RAAS Promotes Cardiac Hypertrophy and Fibrosis.
    Böckmann I; Lischka J; Richter B; Deppe J; Rahn A; Fischer DC; Heineke J; Haffner D; Leifheit-Nestler M
    Int J Mol Sci; 2019 Sep; 20(18):. PubMed ID: 31540546
    [TBL] [Abstract][Full Text] [Related]  

  • 16. FGF23 induced left ventricular hypertrophy mediated by FGFR4 signaling in the myocardium is attenuated by soluble Klotho in mice.
    Han X; Cai C; Xiao Z; Quarles LD
    J Mol Cell Cardiol; 2020 Jan; 138():66-74. PubMed ID: 31758962
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Association of Fibroblast Growth Factor 23 With Atrial Fibrillation in Chronic Kidney Disease, From the Chronic Renal Insufficiency Cohort Study.
    Mehta R; Cai X; Lee J; Scialla JJ; Bansal N; Sondheimer JH; Chen J; Hamm LL; Ricardo AC; Navaneethan SD; Deo R; Rahman M; Feldman HI; Go AS; Isakova T; Wolf M;
    JAMA Cardiol; 2016 Aug; 1(5):548-56. PubMed ID: 27434583
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Fibroblast growth factor 23, left ventricular mass, and left ventricular hypertrophy in community-dwelling older adults.
    Jovanovich A; Ix JH; Gottdiener J; McFann K; Katz R; Kestenbaum B; de Boer IH; Sarnak M; Shlipak MG; Mukamal KJ; Siscovick D; Chonchol M
    Atherosclerosis; 2013 Nov; 231(1):114-9. PubMed ID: 24125420
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Relationship of FGF23 to indexed left ventricular mass in children with non-dialysis stages of chronic kidney disease.
    Sinha MD; Turner C; Booth CJ; Waller S; Rasmussen P; Goldsmith DJ; Simpson JM
    Pediatr Nephrol; 2015 Oct; 30(10):1843-52. PubMed ID: 25975437
    [TBL] [Abstract][Full Text] [Related]  

  • 20. DMP1 prevents osteocyte alterations, FGF23 elevation and left ventricular hypertrophy in mice with chronic kidney disease.
    Dussold C; Gerber C; White S; Wang X; Qi L; Francis C; Capella M; Courbon G; Wang J; Li C; Feng JQ; Isakova T; Wolf M; David V; Martin A
    Bone Res; 2019; 7():12. PubMed ID: 31044094
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.